Full Text View
Tabular View
No Study Results Posted
Related Studies
Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms
This study has been completed.
First Received: September 12, 2005   Last Updated: October 28, 2008   History of Changes
Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00226551
  Purpose

Single nucleotide polymorphisms at codon 46 and 79 of the gene encoding for the ß2 adrenergic receptor (ß2AR) modify its pharmacological properties and may alter the response to ß2AR agonists. The goal of the present study was to evaluate the role played by the Arg16Gly and Gln27Glu polymorphisms on isoproterenol induced relaxation of internal mammary arteries segments ex-vivo.

Internal mammary leftover segments were collected from 96 patients undergoing coronary artery bypass graft operation. Four rings that were prepared from each specimen were allowed to reach equilibrium with physiological Krebs solution prior to precontraction with U46619. Using the organ bath technique, cumulative dose response curve of isoproterenol was constructed and mean EC50 calculated for each patient.


Condition Intervention
Coronary Disease
Drug: Isoproterenol

MedlinePlus related topics: Coronary Artery Disease
Drug Information available for: Isoproterenol hydrochloride Isoproterenol sulfate Isoproterenol
U.S. FDA Resources
Study Type: Interventional
Study Design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Official Title: ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Mean Ec50% in response to rising concentration of isoproterenol

Estimated Enrollment: 100
Study Start Date: August 1999
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients scheduled to undergo coronary artery bypass graft operation

Exclusion Criteria:

  • Chronic treatment with corticosteroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00226551

Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
  More Information

No publications provided by Hadassah Medical Organization

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: yc19558-HMO-CTIL
Study First Received: September 12, 2005
Last Updated: October 28, 2008
ClinicalTrials.gov Identifier: NCT00226551     History of Changes
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:
Arterial Occlusive Diseases
Neurotransmitter Agents
Heart Diseases
Adrenergic Agents
Adrenergic beta-Agonists
Myocardial Ischemia
Vascular Diseases
Anti-Asthmatic Agents
Cardiovascular Agents
Ischemia
Arteriosclerosis
Isoproterenol
Adrenergic Agonists
Coronary Disease
Peripheral Nervous System Agents
Bronchodilator Agents
Coronary Artery Disease

Additional relevant MeSH terms:
Respiratory System Agents
Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Cardiotonic Agents
Myocardial Ischemia
Physiological Effects of Drugs
Arteriosclerosis
Adrenergic Agonists
Therapeutic Uses
Cardiovascular Diseases
Arterial Occlusive Diseases
Heart Diseases
Adrenergic beta-Agonists
Sympathomimetics
Vascular Diseases
Anti-Asthmatic Agents
Cardiovascular Agents
Protective Agents
Isoproterenol
Pharmacologic Actions
Coronary Disease
Autonomic Agents
Peripheral Nervous System Agents
Bronchodilator Agents
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009